Veracyte Appoints Dr. Kevin Haas as Chief Development and Technology Officer
summarizeSummary
Veracyte announced the appointment of Dr. Kevin Haas, formerly of Myriad Genetics, as its new Chief Development and Technology Officer, effective March 24, 2026, a strategic move to enhance its technology and development capabilities.
check_boxKey Events
-
New Chief Development and Technology Officer Appointed
Dr. Kevin Haas has been appointed as Veracyte's Chief Development and Technology Officer, effective March 24, 2026.
-
Strategic Executive Hire from Competitor
Dr. Haas previously served as Chief Technology Officer at Myriad Genetics, Inc., bringing valuable experience in genetic testing and precision medicine to Veracyte.
-
Compensation Package Detailed
His compensation includes an annual base salary of $500,000, eligibility for a 55% target annual bonus, and equity awards with a target value of $3,000,000.
auto_awesomeAnalysis
Veracyte has appointed Dr. Kevin Haas, previously the Chief Technology Officer at Myriad Genetics, as its new Chief Development and Technology Officer. This is a significant strategic hire, bringing in an executive with a strong background in genetic testing and precision medicine from a competitor. His expertise is expected to bolster Veracyte's technology and development initiatives. The compensation package, including a $500,000 base salary and $3,000,000 in target equity awards, reflects the importance of this role and the company's investment in its leadership team.
At the time of this filing, VCYT was trading at $32.92 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $22.61 to $50.71. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.